AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN DIEGO -- Morbidity and mortality remain high in patients with antiphos-pholipid syndrome despite current therapy with anticoagulants and low-dose aspirin, Dr. Ricard Cervera reported in a late-breaking poster session at the annual meeting of the American College of Rheumatology.
This observation has emerged from the ongoing Euro-Phospholipid Project, which began in 1999 and includes 1,000 patients from 13 European countries. The mean age of the patients is 47 years, and 82% are female. On enrollment, all met proposed preliminary criteria for the classification of definite antiphospholipid syndrome (APS).
During 5 years of follow-up, 20% of patients have had a thrombotic event. Among patients with thrombotic events were 24 who presented with strokes, 24 with transient ischemic attacks, 21 with deep vein thrombosis, 21 with pulmonary embolism, and 17 with skin ulcers.
Additionally, five patients developed catastrophic APS, according to Dr. Cervera of the Hospital Clinic, Barcelona.
The main APS therapies being used were oral anticoagulants, which were taken by 42% of patients, and low-dose aspirin, which was used by 35%. At the time of the thrombotic event, 121 patients were ...
Source: HighBeam Research, Morbidity, mortality still high in patients with APS.(Clinical Rounds)